公开(公告)号：US20150335658A1

公开(公告)日：2015-11-26

申请号：US14812431

申请日：2015-07-29

申请人： Bayer Intellectual Property GmbH

发明人： Jochen SCHUMACHER ,  Manfred SUESSE ,  Michael DITTGEN ,  Stephan MLETZKO ,  Jan-Peter INGWERSEN ,  Thomas LANGGUTH ,  Dirk SCHENK ,  Hubert KAFFL

IPC分类号： A61K31/567 ,  A61M35/00 ,  A61K9/70

CPC分类号： A61K31/567 ,  A61K9/0014 ,  A61K9/7084 ,  A61K47/08 ,  A61K47/12 ,  A61K47/22 ,  A61M35/00

摘要： The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV-radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.

摘要翻译： 本发明涉及由背层，至少一种含有活性物质的基质和任选的取出膜和UV-辐射吸收剂组成的UV稳定透皮治疗系统（TTS）。 含有所述紫外线吸收剂的粘合剂层被布置在背层和含有活性物质的基质之间，所述活性物质尽可能远离表面，分离层设置在包含所述紫外线吸收剂的粘合剂层和 含有活性物质的基质，该活性物质尽可能远离活性物质和紫外线吸收剂不可渗透的表面。 本发明的透皮治疗系统表现出高稳定性，并且没有含有光敏物质的现有TTS的不便。

公开(公告)号：US20140109916A1

公开(公告)日：2014-04-24

申请号：US14141697

申请日：2013-12-27

申请人： Bayer Intellectual Property GmbH

发明人： Thomas LANGGUTH ,  Stefan BRACHT ,  Michael DITTGEN ,  Petra HUBER ,  Dirk SCHENK

IPC分类号： A61K47/32 ,  A61K9/70 ,  A61K31/567 ,  A61K31/57

CPC分类号： A61K47/32 ,  A61K9/70 ,  A61K9/7053 ,  A61K9/7061 ,  A61K9/7076 ,  A61K31/56 ,  A61K31/567 ,  A61K31/57

摘要： The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.

摘要翻译： 本发明涉及包含含有低含量激素的药物含量层（如孕二烯酮）和任选的雌激素（如乙炔雌二醇）的贴剂。 在向女性施用贴剂时，在稳定状态条件下达到至少1.0ng / ml的Gestodene的血浆水平，而不需要在含药层中掺入渗透促进剂或渗透促进剂。 令人满意的激素水平也可以在至少1周的时间内达到，使补丁适用于女性避孕方法，每周施用补片的概念。